Shilpa Medicare Shares Surge Up to 16% Following Record Q1 Financials

MUMBAI — Shares of Shilpa Medicare Ltd jumped up to 16% in intra-day trading on August 5, 2026, touching a lifetime high of Rs 753.85 on the National Stock Exchange following the release of record-breaking financial results for the first quarter of FY27. The rally reflects strong investor confidence in the company's expanding market footprint across formulation markets, robust operational growth, and scaling business metrics.

The pharmaceutical manufacturer closed trading at Rs 721.75, up 11.96% on the day after briefly scaling the Rs 753.85 level.

Record Profit and Revenue Performance

For the quarter ended June 30, 2026 (Q1 FY27), Shilpa Medicare reported a consolidated net profit of Rs 101 crore. This represents a 114.89% increase compared to the Rs 47 crore net profit recorded during the corresponding period of the previous financial year.

The company's top-line performance experienced significant acceleration, with total revenue from operations expanding 45% year-on-year to Rs 466 crore, compared to Rs 321 crore in Q1 FY26.

Operational earnings similarly tracked upward momentum. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) surged 48.6% year-on-year to Rs 136.2 crore. EBITDA margins expanded by 73 basis points, moving to 29.25% from 28.52% in the prior-year period.

Operational Segment Highlights

Growth during the quarter was distributed across multiple core operations, with key contributions coming from active pharmaceutical ingredient (API) divisions and international formulations:

• Active Pharmaceutical Ingredients (API): Revenue from the API division increased by approximately 15% year-on-year, driven by a balance of captive consumption and expanding external market demand.

• Formulations Business: Domestic formulation sales rose 179% year-on-year, supported by sustained commercial adoption across local channels. European formulation revenue expanded 84% year-on-year to Rs 57 crore, boosted by new product launches and increased market presence.

• Novel Products Business: Excluding one-off licensing revenue, the company’s novel products division more than doubled its revenue year-on-year.

Corporate and Regulatory Developments

The earnings release comes after strategic corporate and regulatory milestones achieved during the summer:

1. Strategic Partnerships: In June 2026, Shilpa Medicare’s wholly owned subsidiary, Shilpa Biologicals, entered into a joint co-development and supply arrangement with Finland-based Orion Corporation for a Nivolumab biosimilar.

2. Credit Rating Upgrades: In July 2026, credit rating agency India Ratings upgraded the long-term credit ratings of Shilpa Medicare and its subsidiary, Shilpa Pharma Lifesciences, to IND AA-/Stable.

3. Pipeline Progress: Management reconfirmed plans to submit its Drug Master File (DMF) for Semaglutide in the first half of FY27, with commercial European shipments projected to commence in the second half of the fiscal year.

Official Sources Statement

"According to official financial disclosures submitted to stock exchanges, operational performance across core dosage and API verticals drove the consolidated margin expansion during the quarter ending June 2026," company filings noted.

Strategic Quote

"The quarterly performance reflects strong demand momentum across domestic formulations alongside sustained expansion in European geographies," company leadership stated in documentation released to market participants.

Why It Matters

The quarter-one operating results highlight shifting market dynamics in specialized API formulations and complex biosimilars. For retail and institutional investors, the combination of upgraded credit profiles, expanding operating margins, and entering new European supply channels provides clearer visibility into the company's long-term earnings potential and financial leverage management.

Key Facts at a Glance

• Q1 FY27 Consolidated Net Profit: Rs 101 crore (Up 115% YoY from Rs 47 crore).

• Q1 FY27 Revenue from Operations: Rs 466 crore (Up 45% YoY from Rs 321 crore).

• Intraday Stock High: Rs 753.85 per share on NSE (Record high).

• EBITDA Margin: 29.25% (Expanded from 28.52% in Q1 FY26).

• European Formulations Revenue: Rs 57 crore (Up 84% YoY).

Frequently Asked Questions (FAQ)

Q1: Why did Shilpa Medicare shares gain up to 16%?

Shilpa Medicare shares surged following the announcement of record Q1 FY27 earnings, highlighted by a 115% surge in net profit and a 45% growth in total revenue.

Q2: What drove the revenue growth for Shilpa Medicare in Q1 FY27?

Revenue growth was driven by an 84% surge in European formulation sales, a 179% rise in domestic formulation revenue, a 15% increase in API sales, and strong growth in the novel products segment.

Q3: What upcoming product milestones has Shilpa Medicare announced?

Shilpa Medicare plans to file the Drug Master File (DMF) for Semaglutide in H1 FY27 and expects to initiate commercial supplies in European markets during H2 FY27.

Source: Official regulatory disclosures filed by Shilpa Medicare Ltd with Indian stock exchanges.